---
layout: default
title: Propantheline
description: "Propantheline çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 2 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 142
evidence_level: L3
indication_count: 2
---

# Propantheline

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>2</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Propanthelineï¼šå¾æ¶ˆåŒ–æ€§æ½°ç˜åˆ°èƒƒåäºŒæŒ‡è…¸ç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Propantheline å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Propantheline æ˜¯ä¸€ç¨®å‰¯äº¤æ„Ÿç¥ç¶“é˜»æ–·åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼èƒƒæ½°ç˜ã€åäºŒæŒ‡è…¸æ½°ç˜å’Œèƒƒç‚çš„æ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**èƒƒåäºŒæŒ‡è…¸ç‚ (Gastroduodenitis)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **5 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | èƒƒæ½°ç˜ã€åäºŒæŒ‡è…¸æ½°ç˜ã€èƒƒç‚ã€èƒƒé…¸éå¤š |
| é æ¸¬æ–°é©æ‡‰ç—‡ | gastroduodenitisã€peptic ulcer disease |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.90% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ï¼ˆéƒ¨åˆ†è¨±å¯è­‰å·²è¨»éŠ·ï¼‰ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Go |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. gastroduodenitis</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.90%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Propantheline æ˜¯ä¸€ç¨®æŠ—è†½é¹¼è—¥ç‰©ï¼Œèƒ½å¤ é˜»æ–·å‰¯äº¤æ„Ÿç¥ç¶“çš„ä½œç”¨ï¼Œæ¸›å°‘èƒƒé…¸åˆ†æ³Œä¸¦é™ä½èƒƒè…¸é“çš„è •å‹•å’Œç—™æ”£ã€‚é€™äº›ä½œç”¨æ©Ÿè½‰ä½¿å…¶æˆç‚ºæ²»ç™‚æ¶ˆåŒ–æ€§æ½°ç˜å’Œèƒƒç‚çš„æœ‰æ•ˆè—¥ç‰©ã€‚

èƒƒåäºŒæŒ‡è…¸ç‚æ˜¯æŒ‡èƒƒå’ŒåäºŒæŒ‡è…¸åŒæ™‚ç™¼ç”Ÿçš„ç‚ç—‡ï¼Œå…¶ç—…ç†æ©Ÿè½‰èˆ‡èƒƒæ½°ç˜å’ŒåäºŒæŒ‡è…¸æ½°ç˜é«˜åº¦ç›¸é—œã€‚Propantheline é€éä»¥ä¸‹æ©Ÿè½‰å¯èƒ½æœ‰åŠ©æ–¼æ²»ç™‚èƒƒåäºŒæŒ‡è…¸ç‚ï¼š

1. æŠ‘åˆ¶èƒƒé…¸åˆ†æ³Œï¼Œæ¸›å°‘é…¸æ€§ç’°å¢ƒå°é»è†œçš„åˆºæ¿€
2. æ¸›å°‘èƒƒè…¸é“è •å‹•ï¼Œé™ä½æ©Ÿæ¢°æ€§æå‚·
3. ç·©è§£èƒƒè…¸ç—™æ”£ï¼Œæ¸›è¼•ç–¼ç—›ç—‡ç‹€

ç”±æ–¼åŸé©æ‡‰ç—‡å’Œæ–°é æ¸¬é©æ‡‰ç—‡åœ¨è§£å‰–ä½ç½®å’Œç—…ç†æ©Ÿè½‰ä¸Šé«˜åº¦ç›¸ä¼¼ï¼Œé€™å€‹é æ¸¬å…·æœ‰å¾ˆå¼·çš„åˆç†æ€§ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [6342335](https://pubmed.ncbi.nlm.nih.gov/6342335/) | 1983 | RCT | Acta Med Scand | Cimetidine ä½µç”¨ä½åŠ‘é‡ propantheline æ²»ç™‚èƒƒåäºŒæŒ‡è…¸æ½°ç˜ |
| [761954](https://pubmed.ncbi.nlm.nih.gov/761954/) | 1979 | Journal Article | Int J Clin Pharmacol | Trithiozine èˆ‡ propantheline åœ¨èƒƒåˆ†æ³ŒæŠ‘åˆ¶ä½œç”¨çš„æ¯”è¼ƒ |
| [4798570](https://pubmed.ncbi.nlm.nih.gov/4798570/) | 1973 | Journal Article | Minerva Med | èƒƒåäºŒæŒ‡è…¸æ½°ç˜çš„ä¿å®ˆæ²»ç™‚ |
| [13392433](https://pubmed.ncbi.nlm.nih.gov/13392433/) | 1956 | Journal Article | Vie Med | Propantheline ç”¨æ–¼èƒƒåäºŒæŒ‡è…¸æ½°ç˜çš„æŠ—è†½é¹¼æ²»ç™‚ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. irritable bowel syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.16%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.16%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è¼¸å­—ç¬¬002640è™Ÿ | ç›Šèƒƒå¯§ | éŒ åŠ‘ | èƒƒã€åäºŒæŒ‡è…¸æ½°ç˜ã€èƒƒç‚ã€å­å®®ç—™æ”£ï¼ˆå·²è¨»éŠ·ï¼‰ |
| å…§è¡›è—¥è£½å­—ç¬¬001973è™Ÿ | èƒƒç™¾åº·ç‰‡ | éŒ åŠ‘ | æ€¥æ…¢æ€§èƒƒç‚ã€èƒƒé…¸éå¤šã€èƒƒç—›ã€èƒƒåŠåäºŒæŒ‡è…¸æ½°ç˜ï¼ˆå·²è¨»éŠ·ï¼‰ |

## å®‰å…¨æ€§è€ƒé‡

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚

æŠ—è†½é¹¼è—¥ç‰©çš„å¸¸è¦‹æ³¨æ„äº‹é …ï¼š
- å£ä¹¾
- è¦–åŠ›æ¨¡ç³Š
- å°¿æ»¯ç•™ï¼ˆç‰¹åˆ¥æ˜¯æ”è­·è…ºè‚¥å¤§æ‚£è€…ï¼‰
- ä¾¿ç§˜

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šUse of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be...
- å»ºè­°ï¼šAlcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect the...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é«˜è¡€å£“ (Hypertension)** ğŸ”´ Major
- Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.

**Fever** ğŸ”´ Major
- Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.

**Psychotic Disorders** ğŸŸ¡ Moderate
- Toxic psychosis manifested as confusion, disorientation, agitation, excitation, memory impairment, delusions and hallucinations may develop at toxic and therapeutic dosages of antimuscarinic agents.  Therapy with these agents should be administered c...

**Arrhythmias, Cardiac** ğŸŸ¢ Minor
- Patients with tachycardia should be supervised closely during treatment with anticholinergic agents.  Tachycardia is produced by blocking normal vagal inhibition of the SA node.  Paradoxically, bradycardia may occur due to central vagal stimulation w...

**Diabetic Neuropathies** ğŸŸ¢ Minor
- Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in mal...

*å¦æœ‰ 5 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šGo**

**ç†ç”±ï¼š**
èƒƒåäºŒæŒ‡è…¸ç‚èˆ‡ propantheline çš„åŸé©æ‡‰ç—‡ï¼ˆèƒƒæ½°ç˜ã€åäºŒæŒ‡è…¸æ½°ç˜ã€èƒƒç‚ï¼‰åœ¨ç—…ç†æ©Ÿè½‰ä¸Šé«˜åº¦ç›¸é—œã€‚Propantheline çš„æŠ—è†½é¹¼ä½œç”¨ï¼ˆæŠ‘åˆ¶èƒƒé…¸åˆ†æ³Œã€æ¸›å°‘èƒƒè…¸è •å‹•ï¼‰å°æ–¼èƒƒåäºŒæŒ‡è…¸ç‚çš„æ²»ç™‚å…·æœ‰æ˜ç¢ºçš„è—¥ç†å­¸åŸºç¤ã€‚æ–‡ç»ä¸­å·²æœ‰ propantheline ç”¨æ–¼èƒƒåäºŒæŒ‡è…¸æ½°ç˜æ²»ç™‚çš„è‡¨åºŠç ”ç©¶ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ç¢ºèªå°ç£ç›®å‰æ˜¯å¦æœ‰æœ‰æ•ˆçš„è¨±å¯è­‰ï¼ˆéƒ¨åˆ†å·²è¨»éŠ·ï¼‰
- è©•ä¼°èˆ‡ç¾ä»£è³ªå­æ³µæŠ‘åˆ¶åŠ‘ï¼ˆPPIï¼‰ç›¸æ¯”çš„å®šä½
- åˆ¶å®šé©ç•¶çš„åŠ‘é‡æ–¹æ¡ˆ


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Inositol]({{ "/drugs/inositol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Vinorelbine]({{ "/drugs/vinorelbine/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dorzolamide]({{ "/drugs/dorzolamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Propanthelineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/propantheline/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_propantheline,
  title = {Propanthelineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/propantheline/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
